Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT02671357 Completed - Clinical trials for Pancreatic Neoplasms; Periampullary Neoplasms

Enhanced Recovery After Minimally Invasive Pancreaticoduodenectomy

ERAMIP
Start date: March 2016
Phase:
Study type: Observational

This prospective observational cohort study aims to improve the postoperative course after minimally invasive pancreaticoduodenectomy (MIP) with stented pancreaticogastrostomy (sPG) for pancreatic head or peri-ampullary neoplasms. Patients are submitted to an enhanced recovery after surgery (ERAS) program with early enteral nutrition (EEN).

NCT ID: NCT02670265 Completed - Pancreatic Cancer Clinical Trials

Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions

NUPAN
Start date: June 2012
Phase: N/A
Study type: Interventional

Patients with biliopancreatic tumors are at risk for malnutrition and have to undergo many procedures for diagnostic workup that require fasting periods. In a prospective randomized monocentric study we evaluate the effect of additional parenteral nutrition on weight loss, nutritional status, quality of life and length of hospital stay.

NCT ID: NCT02657330 Completed - Pancreatic Cancer Clinical Trials

Study of SBP-101 in Pancreatic Cancer

Start date: January 2016
Phase: Phase 1
Study type: Interventional

This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD). In addition, this study will also assess the pharmacokinetic (PK) profile and preliminary efficacy of SBP-101.

NCT ID: NCT02651987 Completed - Clinical trials for Midgut Neuroendocrine Tumours

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

CLARINET FORTE
Start date: December 15, 2015
Phase: Phase 2
Study type: Interventional

This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine tumours (NETs) once they have progressed on the standard dose of lanreotide Autogel® 120 mg every 28 days.

NCT ID: NCT02650804 Completed - Pancreatic Cancer Clinical Trials

BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients

Start date: July 6, 2016
Phase: Phase 2
Study type: Interventional

This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of BPM31510 administered over 144-hours (two 72-hour 110mg/Kg doses) continuous intravenous (IV) infusion in combination with gemcitabine in advanced pancreatic cancer patients as 2nd / 3rd line therapy. The study will enroll up to 25 patients in the US and Europe.

NCT ID: NCT02648880 Completed - Pancreatic Cancer Clinical Trials

Preoperative Exercise in Pancreatic Cancer

Start date: May 10, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effects of a preoperative exercise program in patients with pancreatic cancer preparing for surgery. Preoperative exercise programs have been shown to be effective in other cancer populations, but have not been investigated in patients with pancreatic cancer. The outcomes in this study will be changes in physical fitness, function, and postoperative outcomes. This investigation is a non-randomized control trial, with participants assigned to receive the preoperative exercise intervention in addition to standard care, or standard care alone if unable to commit to an exercise program for practical reasons. Possible mediators for the effects of exercise on postoperative outcomes will also be assessed, including psychological outcomes and markers of systemic inflammation. These measures will be assessed in all participants prior to program initiation, prior to surgery, and after surgery. Changes in these measures in response to exercise will be assessed, as well as the ability of the preoperative measures to predict postoperative outcomes.

NCT ID: NCT02648282 Completed - Pancreatic Cancer Clinical Trials

Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

Start date: July 18, 2016
Phase: Phase 2
Study type: Interventional

This study will be looking at whether combining cyclophosphamide, pembrolizumab (an antibody that blocks negative signals to T cells), GVAX (pancreatic cancer vaccine), and SBRT (focused radiation) is effective (anti-tumor activity) and safe in patients with locally advanced pancreatic cancer.

NCT ID: NCT02639026 Completed - Breast Cancer Clinical Trials

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Start date: January 26, 2016
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to determine how best to combine hypofractionated radiotherapy, MEDI4736, and tremelimumab and to determine how safe and tolerable hypofractionated radiotherapy, MEDI4736, and tremelimumab are when given together in subjects with metastatic, melanoma, non small cell lung cancer (NSCLC), breast cancer, and pancreatic cancer.

NCT ID: NCT02637596 Completed - Pancreatic Cancer Clinical Trials

Quality of Life After Radiofrequency Ablation of Pancreatic Cancer

Start date: February 2013
Phase: N/A
Study type: Interventional

A prospective clinical study evaluating quality of life (QoL) in pancreatic cancer patients treated with intraoperative radiofrequency ablation (RFA).

NCT ID: NCT02626195 Completed - Pancreatic Cancer Clinical Trials

Preoperative Nutritional Support in Malnutritional Cancer Patients

Start date: October 2013
Phase: N/A
Study type: Interventional

Malnutrition patients are known to have more postoperative complications and mortality. And most of hepatobiliary-pancreatic cancer surgeries accompany high postoperative morbidity and mortality rate. Therefore for the malnourished patients anticipating major surgery, preoperative nutritional support is recommended according to the ASPEN (American society of parenteral and enteral nutrition) and ESPEN (European society of parenteral and enteral nutrition) guideline. However there is no prospective trial to prove the clinical impact of preoperative nutritional support for malnourished patients. The purpose of this study is to evaluate the clinical impact of preoperative nutritional support for malnourished cancer patients anticipating HBP surgery. Primary objective is to compare the complication rate and secondary object is to compare the quality of life, hospital stay and cost.